In addition to glycemic control, the ADA recommends weight management for patients with type 2 diabetes (T2D) with overweight or obesity. This analysis explored the association between weight loss and patients’ quality of life using pooled data from the SURPASS clinical trials, regardless of treatment and dosing. SURPASS 1 to 5 participants achieving ≥5%, ≥10%, or ≥15% weight loss were assessed for patient-reported outcomes (PRO) at baseline and endpoint. Weight related PROs investigated were Ability to Perform Physical Activities of Daily Living (APPADL) , Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) , Impact of Weight on Self-Perceptions (IW-SP) , and other measures were the EQ-5D-5L and Diabetes Treatment Satisfaction Questionnaire change (DTSQc) . Higher PRO scores indicate better outcomes. At endpoint, improvements were observed from baseline in all assessed PRO measures across weight loss categories (Table) . As we narrow the groups to those with higher weight loss percentages, we observed greater improvements in APPADL, IWQOL-Lite-CT, IW-SP, and EQ VAS scores. EQ-5D-5L index score changes and the DTSQc scores also increased but to a lesser extent. Weight loss was associated with improved quality of life with greater improvement seen in higher percentages of weight loss in patients with T2D, regardless of therapy.
K. Boye: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. V. Thieu: None. M. Yu: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. H. Sapin: Employee; Eli Lilly and Company.
Eli Lilly and Company